nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydromorphone—CYP2C9—Teniposide—lymphatic system cancer	0.101	0.35	CbGbCtD
Hydromorphone—CYP3A4—Cytarabine—lymphatic system cancer	0.0596	0.207	CbGbCtD
Hydromorphone—CYP3A4—Teniposide—lymphatic system cancer	0.0587	0.203	CbGbCtD
Hydromorphone—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0411	0.142	CbGbCtD
Hydromorphone—CYP3A4—Vincristine—lymphatic system cancer	0.0283	0.0979	CbGbCtD
Hydromorphone—Malaise—Bleomycin—lymphatic system cancer	0.00123	0.00172	CcSEcCtD
Hydromorphone—Pruritus—Teniposide—lymphatic system cancer	0.00122	0.00171	CcSEcCtD
Hydromorphone—Arrhythmia—Carmustine—lymphatic system cancer	0.00122	0.00171	CcSEcCtD
Hydromorphone—Leukopenia—Bleomycin—lymphatic system cancer	0.00122	0.00171	CcSEcCtD
Hydromorphone—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00121	0.00171	CcSEcCtD
Hydromorphone—Cardiac disorder—Vincristine—lymphatic system cancer	0.00121	0.0017	CcSEcCtD
Hydromorphone—Body temperature increased—Fludarabine—lymphatic system cancer	0.0012	0.00168	CcSEcCtD
Hydromorphone—Mental disorder—Carmustine—lymphatic system cancer	0.00119	0.00168	CcSEcCtD
Hydromorphone—Malnutrition—Carmustine—lymphatic system cancer	0.00119	0.00167	CcSEcCtD
Hydromorphone—Erythema—Carmustine—lymphatic system cancer	0.00119	0.00167	CcSEcCtD
Hydromorphone—Cough—Bleomycin—lymphatic system cancer	0.00119	0.00167	CcSEcCtD
Hydromorphone—Angiopathy—Vincristine—lymphatic system cancer	0.00118	0.00166	CcSEcCtD
Hydromorphone—Diarrhoea—Teniposide—lymphatic system cancer	0.00118	0.00166	CcSEcCtD
Hydromorphone—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00117	0.00165	CcSEcCtD
Hydromorphone—Chest pain—Bleomycin—lymphatic system cancer	0.00116	0.00163	CcSEcCtD
Hydromorphone—Myalgia—Bleomycin—lymphatic system cancer	0.00116	0.00163	CcSEcCtD
Hydromorphone—Coma—Methotrexate—lymphatic system cancer	0.00115	0.00162	CcSEcCtD
Hydromorphone—Back pain—Carmustine—lymphatic system cancer	0.00115	0.00161	CcSEcCtD
Hydromorphone—Discomfort—Bleomycin—lymphatic system cancer	0.00114	0.00161	CcSEcCtD
Hydromorphone—Mental disorder—Vincristine—lymphatic system cancer	0.00114	0.0016	CcSEcCtD
Hydromorphone—Chills—Mitoxantrone—lymphatic system cancer	0.00114	0.0016	CcSEcCtD
Hydromorphone—Urine output increased—Methotrexate—lymphatic system cancer	0.00114	0.0016	CcSEcCtD
Hydromorphone—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00113	0.00159	CcSEcCtD
Hydromorphone—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00112	0.00157	CcSEcCtD
Hydromorphone—Confusional state—Bleomycin—lymphatic system cancer	0.00112	0.00157	CcSEcCtD
Hydromorphone—Vision blurred—Carmustine—lymphatic system cancer	0.00112	0.00157	CcSEcCtD
Hydromorphone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00112	0.00157	CcSEcCtD
Hydromorphone—Tremor—Carmustine—lymphatic system cancer	0.00111	0.00156	CcSEcCtD
Hydromorphone—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00111	0.00156	CcSEcCtD
Hydromorphone—Erythema—Mitoxantrone—lymphatic system cancer	0.0011	0.00155	CcSEcCtD
Hydromorphone—Infection—Bleomycin—lymphatic system cancer	0.0011	0.00155	CcSEcCtD
Hydromorphone—Back pain—Vincristine—lymphatic system cancer	0.0011	0.00154	CcSEcCtD
Hydromorphone—Vomiting—Teniposide—lymphatic system cancer	0.0011	0.00154	CcSEcCtD
Hydromorphone—Agitation—Carmustine—lymphatic system cancer	0.00109	0.00153	CcSEcCtD
Hydromorphone—Asthenia—Fludarabine—lymphatic system cancer	0.00109	0.00153	CcSEcCtD
Hydromorphone—Rash—Teniposide—lymphatic system cancer	0.00109	0.00153	CcSEcCtD
Hydromorphone—Dermatitis—Teniposide—lymphatic system cancer	0.00108	0.00153	CcSEcCtD
Hydromorphone—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00108	0.00152	CcSEcCtD
Hydromorphone—Headache—Teniposide—lymphatic system cancer	0.00108	0.00152	CcSEcCtD
Hydromorphone—Pruritus—Fludarabine—lymphatic system cancer	0.00107	0.00151	CcSEcCtD
Hydromorphone—Back pain—Mitoxantrone—lymphatic system cancer	0.00107	0.0015	CcSEcCtD
Hydromorphone—Leukopenia—Carmustine—lymphatic system cancer	0.00106	0.00149	CcSEcCtD
Hydromorphone—Anorexia—Bleomycin—lymphatic system cancer	0.00106	0.00149	CcSEcCtD
Hydromorphone—Agitation—Vincristine—lymphatic system cancer	0.00104	0.00146	CcSEcCtD
Hydromorphone—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00104	0.00146	CcSEcCtD
Hydromorphone—Polyuria—Methotrexate—lymphatic system cancer	0.00104	0.00146	CcSEcCtD
Hydromorphone—Hypotension—Bleomycin—lymphatic system cancer	0.00104	0.00146	CcSEcCtD
Hydromorphone—Diarrhoea—Fludarabine—lymphatic system cancer	0.00104	0.00146	CcSEcCtD
Hydromorphone—Convulsion—Carmustine—lymphatic system cancer	0.00103	0.00145	CcSEcCtD
Hydromorphone—Hypertension—Carmustine—lymphatic system cancer	0.00102	0.00144	CcSEcCtD
Hydromorphone—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00102	0.00144	CcSEcCtD
Hydromorphone—Nausea—Teniposide—lymphatic system cancer	0.00102	0.00144	CcSEcCtD
Hydromorphone—Vertigo—Vincristine—lymphatic system cancer	0.00102	0.00143	CcSEcCtD
Hydromorphone—Leukopenia—Vincristine—lymphatic system cancer	0.00101	0.00143	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00101	0.00142	CcSEcCtD
Hydromorphone—Myalgia—Carmustine—lymphatic system cancer	0.00101	0.00142	CcSEcCtD
Hydromorphone—Chest pain—Carmustine—lymphatic system cancer	0.00101	0.00142	CcSEcCtD
Hydromorphone—Anxiety—Carmustine—lymphatic system cancer	0.00101	0.00142	CcSEcCtD
Hydromorphone—Paraesthesia—Bleomycin—lymphatic system cancer	0.000997	0.0014	CcSEcCtD
Hydromorphone—Malaise—Mitoxantrone—lymphatic system cancer	0.000995	0.0014	CcSEcCtD
Hydromorphone—Dyspnoea—Bleomycin—lymphatic system cancer	0.000989	0.00139	CcSEcCtD
Hydromorphone—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000988	0.00139	CcSEcCtD
Hydromorphone—Convulsion—Vincristine—lymphatic system cancer	0.000982	0.00138	CcSEcCtD
Hydromorphone—Hypertension—Vincristine—lymphatic system cancer	0.000978	0.00138	CcSEcCtD
Hydromorphone—Confusional state—Carmustine—lymphatic system cancer	0.000977	0.00137	CcSEcCtD
Hydromorphone—Decreased appetite—Bleomycin—lymphatic system cancer	0.000965	0.00136	CcSEcCtD
Hydromorphone—Myalgia—Vincristine—lymphatic system cancer	0.000965	0.00136	CcSEcCtD
Hydromorphone—Visual disturbance—Methotrexate—lymphatic system cancer	0.000963	0.00135	CcSEcCtD
Hydromorphone—Cough—Mitoxantrone—lymphatic system cancer	0.000963	0.00135	CcSEcCtD
Hydromorphone—Infection—Carmustine—lymphatic system cancer	0.000962	0.00135	CcSEcCtD
Hydromorphone—Vomiting—Fludarabine—lymphatic system cancer	0.000962	0.00135	CcSEcCtD
Hydromorphone—Convulsion—Mitoxantrone—lymphatic system cancer	0.000956	0.00134	CcSEcCtD
Hydromorphone—Rash—Fludarabine—lymphatic system cancer	0.000954	0.00134	CcSEcCtD
Hydromorphone—Dermatitis—Fludarabine—lymphatic system cancer	0.000954	0.00134	CcSEcCtD
Hydromorphone—Hypertension—Mitoxantrone—lymphatic system cancer	0.000953	0.00134	CcSEcCtD
Hydromorphone—Pain—Bleomycin—lymphatic system cancer	0.000949	0.00133	CcSEcCtD
Hydromorphone—Headache—Fludarabine—lymphatic system cancer	0.000948	0.00133	CcSEcCtD
Hydromorphone—Tachycardia—Carmustine—lymphatic system cancer	0.000946	0.00133	CcSEcCtD
Hydromorphone—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000943	0.00133	CcSEcCtD
Hydromorphone—Chest pain—Mitoxantrone—lymphatic system cancer	0.00094	0.00132	CcSEcCtD
Hydromorphone—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00094	0.00132	CcSEcCtD
Hydromorphone—Myalgia—Mitoxantrone—lymphatic system cancer	0.00094	0.00132	CcSEcCtD
Hydromorphone—Anxiety—Mitoxantrone—lymphatic system cancer	0.000936	0.00132	CcSEcCtD
Hydromorphone—Lethargy—Methotrexate—lymphatic system cancer	0.000932	0.00131	CcSEcCtD
Hydromorphone—Discomfort—Mitoxantrone—lymphatic system cancer	0.000928	0.0013	CcSEcCtD
Hydromorphone—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000925	0.0013	CcSEcCtD
Hydromorphone—Anorexia—Carmustine—lymphatic system cancer	0.000923	0.0013	CcSEcCtD
Hydromorphone—Infection—Vincristine—lymphatic system cancer	0.000919	0.00129	CcSEcCtD
Hydromorphone—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000915	0.00129	CcSEcCtD
Hydromorphone—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000913	0.00128	CcSEcCtD
Hydromorphone—Confusional state—Mitoxantrone—lymphatic system cancer	0.000908	0.00128	CcSEcCtD
Hydromorphone—Nervous system disorder—Vincristine—lymphatic system cancer	0.000907	0.00127	CcSEcCtD
Hydromorphone—Hypotension—Carmustine—lymphatic system cancer	0.000905	0.00127	CcSEcCtD
Hydromorphone—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000901	0.00127	CcSEcCtD
Hydromorphone—Nausea—Fludarabine—lymphatic system cancer	0.000899	0.00126	CcSEcCtD
Hydromorphone—Infection—Mitoxantrone—lymphatic system cancer	0.000895	0.00126	CcSEcCtD
Hydromorphone—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000894	0.00126	CcSEcCtD
Hydromorphone—Shock—Mitoxantrone—lymphatic system cancer	0.000886	0.00125	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000883	0.00124	CcSEcCtD
Hydromorphone—Urticaria—Bleomycin—lymphatic system cancer	0.000882	0.00124	CcSEcCtD
Hydromorphone—Anorexia—Vincristine—lymphatic system cancer	0.000882	0.00124	CcSEcCtD
Hydromorphone—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000879	0.00124	CcSEcCtD
Hydromorphone—Body temperature increased—Bleomycin—lymphatic system cancer	0.000877	0.00123	CcSEcCtD
Hydromorphone—Insomnia—Carmustine—lymphatic system cancer	0.000876	0.00123	CcSEcCtD
Hydromorphone—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000875	0.00123	CcSEcCtD
Hydromorphone—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000871	0.00122	CcSEcCtD
Hydromorphone—Paraesthesia—Carmustine—lymphatic system cancer	0.00087	0.00122	CcSEcCtD
Hydromorphone—Mood swings—Methotrexate—lymphatic system cancer	0.000865	0.00122	CcSEcCtD
Hydromorphone—Hypotension—Vincristine—lymphatic system cancer	0.000864	0.00121	CcSEcCtD
Hydromorphone—Dyspnoea—Carmustine—lymphatic system cancer	0.000864	0.00121	CcSEcCtD
Hydromorphone—Somnolence—Carmustine—lymphatic system cancer	0.000861	0.00121	CcSEcCtD
Hydromorphone—Anorexia—Mitoxantrone—lymphatic system cancer	0.000859	0.00121	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000843	0.00118	CcSEcCtD
Hydromorphone—Decreased appetite—Carmustine—lymphatic system cancer	0.000842	0.00118	CcSEcCtD
Hydromorphone—Hypotension—Mitoxantrone—lymphatic system cancer	0.000842	0.00118	CcSEcCtD
Hydromorphone—Insomnia—Vincristine—lymphatic system cancer	0.000836	0.00118	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000836	0.00118	CcSEcCtD
Hydromorphone—Paraesthesia—Vincristine—lymphatic system cancer	0.00083	0.00117	CcSEcCtD
Hydromorphone—Constipation—Carmustine—lymphatic system cancer	0.000828	0.00116	CcSEcCtD
Hydromorphone—Pain—Carmustine—lymphatic system cancer	0.000828	0.00116	CcSEcCtD
Hydromorphone—Breast disorder—Methotrexate—lymphatic system cancer	0.000825	0.00116	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000821	0.00115	CcSEcCtD
Hydromorphone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000818	0.00115	CcSEcCtD
Hydromorphone—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000809	0.00114	CcSEcCtD
Hydromorphone—Decreased appetite—Vincristine—lymphatic system cancer	0.000804	0.00113	CcSEcCtD
Hydromorphone—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000803	0.00113	CcSEcCtD
Hydromorphone—Somnolence—Mitoxantrone—lymphatic system cancer	0.000801	0.00113	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000798	0.00112	CcSEcCtD
Hydromorphone—Feeling abnormal—Carmustine—lymphatic system cancer	0.000798	0.00112	CcSEcCtD
Hydromorphone—Fatigue—Vincristine—lymphatic system cancer	0.000797	0.00112	CcSEcCtD
Hydromorphone—Asthenia—Bleomycin—lymphatic system cancer	0.000796	0.00112	CcSEcCtD
Hydromorphone—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000793	0.00111	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000792	0.00111	CcSEcCtD
Hydromorphone—Pain—Vincristine—lymphatic system cancer	0.000791	0.00111	CcSEcCtD
Hydromorphone—Constipation—Vincristine—lymphatic system cancer	0.000791	0.00111	CcSEcCtD
Hydromorphone—Asthma—Methotrexate—lymphatic system cancer	0.000789	0.00111	CcSEcCtD
Hydromorphone—Pruritus—Bleomycin—lymphatic system cancer	0.000785	0.0011	CcSEcCtD
Hydromorphone—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000783	0.0011	CcSEcCtD
Hydromorphone—Fatigue—Mitoxantrone—lymphatic system cancer	0.000776	0.00109	CcSEcCtD
Hydromorphone—Pain—Mitoxantrone—lymphatic system cancer	0.00077	0.00108	CcSEcCtD
Hydromorphone—Constipation—Mitoxantrone—lymphatic system cancer	0.00077	0.00108	CcSEcCtD
Hydromorphone—Body temperature increased—Carmustine—lymphatic system cancer	0.000766	0.00108	CcSEcCtD
Hydromorphone—Abdominal pain—Carmustine—lymphatic system cancer	0.000766	0.00108	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000756	0.00106	CcSEcCtD
Hydromorphone—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000742	0.00104	CcSEcCtD
Hydromorphone—Dysuria—Methotrexate—lymphatic system cancer	0.000738	0.00104	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000736	0.00104	CcSEcCtD
Hydromorphone—Abdominal pain—Vincristine—lymphatic system cancer	0.000731	0.00103	CcSEcCtD
Hydromorphone—Body temperature increased—Vincristine—lymphatic system cancer	0.000731	0.00103	CcSEcCtD
Hydromorphone—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000727	0.00102	CcSEcCtD
Hydromorphone—Urticaria—Mitoxantrone—lymphatic system cancer	0.000715	0.00101	CcSEcCtD
Hydromorphone—Hypersensitivity—Carmustine—lymphatic system cancer	0.000714	0.001	CcSEcCtD
Hydromorphone—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000712	0.001	CcSEcCtD
Hydromorphone—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000712	0.001	CcSEcCtD
Hydromorphone—Vomiting—Bleomycin—lymphatic system cancer	0.000706	0.000992	CcSEcCtD
Hydromorphone—Drowsiness—Methotrexate—lymphatic system cancer	0.000704	0.000989	CcSEcCtD
Hydromorphone—Infestation NOS—Methotrexate—lymphatic system cancer	0.000704	0.000989	CcSEcCtD
Hydromorphone—Infestation—Methotrexate—lymphatic system cancer	0.000704	0.000989	CcSEcCtD
Hydromorphone—Depression—Methotrexate—lymphatic system cancer	0.000702	0.000986	CcSEcCtD
Hydromorphone—Rash—Bleomycin—lymphatic system cancer	0.0007	0.000984	CcSEcCtD
Hydromorphone—Dermatitis—Bleomycin—lymphatic system cancer	0.000699	0.000983	CcSEcCtD
Hydromorphone—Asthenia—Carmustine—lymphatic system cancer	0.000695	0.000977	CcSEcCtD
Hydromorphone—Stomatitis—Methotrexate—lymphatic system cancer	0.000686	0.000964	CcSEcCtD
Hydromorphone—Hypersensitivity—Vincristine—lymphatic system cancer	0.000681	0.000958	CcSEcCtD
Hydromorphone—Sweating—Methotrexate—lymphatic system cancer	0.000675	0.000948	CcSEcCtD
Hydromorphone—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000665	0.000935	CcSEcCtD
Hydromorphone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000664	0.000933	CcSEcCtD
Hydromorphone—Asthenia—Vincristine—lymphatic system cancer	0.000664	0.000933	CcSEcCtD
Hydromorphone—Diarrhoea—Carmustine—lymphatic system cancer	0.000663	0.000932	CcSEcCtD
Hydromorphone—Nausea—Bleomycin—lymphatic system cancer	0.000659	0.000927	CcSEcCtD
Hydromorphone—Asthenia—Mitoxantrone—lymphatic system cancer	0.000646	0.000908	CcSEcCtD
Hydromorphone—Dizziness—Carmustine—lymphatic system cancer	0.000641	0.000901	CcSEcCtD
Hydromorphone—Diarrhoea—Vincristine—lymphatic system cancer	0.000633	0.00089	CcSEcCtD
Hydromorphone—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000624	0.000877	CcSEcCtD
Hydromorphone—Urethral disorder—Methotrexate—lymphatic system cancer	0.000619	0.00087	CcSEcCtD
Hydromorphone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000616	0.000866	CcSEcCtD
Hydromorphone—Vomiting—Carmustine—lymphatic system cancer	0.000616	0.000866	CcSEcCtD
Hydromorphone—Dizziness—Vincristine—lymphatic system cancer	0.000612	0.00086	CcSEcCtD
Hydromorphone—Rash—Carmustine—lymphatic system cancer	0.000611	0.000859	CcSEcCtD
Hydromorphone—Dermatitis—Carmustine—lymphatic system cancer	0.00061	0.000858	CcSEcCtD
Hydromorphone—Visual impairment—Methotrexate—lymphatic system cancer	0.000609	0.000856	CcSEcCtD
Hydromorphone—Headache—Carmustine—lymphatic system cancer	0.000607	0.000853	CcSEcCtD
Hydromorphone—Eye disorder—Methotrexate—lymphatic system cancer	0.00059	0.00083	CcSEcCtD
Hydromorphone—Tinnitus—Methotrexate—lymphatic system cancer	0.000589	0.000828	CcSEcCtD
Hydromorphone—Vomiting—Vincristine—lymphatic system cancer	0.000588	0.000827	CcSEcCtD
Hydromorphone—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000586	0.000824	CcSEcCtD
Hydromorphone—Rash—Vincristine—lymphatic system cancer	0.000583	0.00082	CcSEcCtD
Hydromorphone—Dermatitis—Vincristine—lymphatic system cancer	0.000583	0.000819	CcSEcCtD
Hydromorphone—Headache—Vincristine—lymphatic system cancer	0.000579	0.000814	CcSEcCtD
Hydromorphone—Nausea—Carmustine—lymphatic system cancer	0.000575	0.000809	CcSEcCtD
Hydromorphone—Angiopathy—Methotrexate—lymphatic system cancer	0.000573	0.000806	CcSEcCtD
Hydromorphone—Vomiting—Mitoxantrone—lymphatic system cancer	0.000573	0.000805	CcSEcCtD
Hydromorphone—Immune system disorder—Methotrexate—lymphatic system cancer	0.00057	0.000802	CcSEcCtD
Hydromorphone—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000569	0.0008	CcSEcCtD
Hydromorphone—Rash—Mitoxantrone—lymphatic system cancer	0.000568	0.000798	CcSEcCtD
Hydromorphone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000567	0.000798	CcSEcCtD
Hydromorphone—Chills—Methotrexate—lymphatic system cancer	0.000567	0.000797	CcSEcCtD
Hydromorphone—Headache—Mitoxantrone—lymphatic system cancer	0.000564	0.000793	CcSEcCtD
Hydromorphone—Mental disorder—Methotrexate—lymphatic system cancer	0.000553	0.000778	CcSEcCtD
Hydromorphone—Erythema—Methotrexate—lymphatic system cancer	0.00055	0.000773	CcSEcCtD
Hydromorphone—Malnutrition—Methotrexate—lymphatic system cancer	0.00055	0.000773	CcSEcCtD
Hydromorphone—Nausea—Vincristine—lymphatic system cancer	0.000549	0.000772	CcSEcCtD
Hydromorphone—Dysgeusia—Methotrexate—lymphatic system cancer	0.000538	0.000757	CcSEcCtD
Hydromorphone—Nausea—Mitoxantrone—lymphatic system cancer	0.000535	0.000752	CcSEcCtD
Hydromorphone—Back pain—Methotrexate—lymphatic system cancer	0.000532	0.000748	CcSEcCtD
Hydromorphone—Vision blurred—Methotrexate—lymphatic system cancer	0.000518	0.000728	CcSEcCtD
Hydromorphone—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00051	0.000717	CcSEcCtD
Hydromorphone—Malaise—Methotrexate—lymphatic system cancer	0.000496	0.000697	CcSEcCtD
Hydromorphone—Vertigo—Methotrexate—lymphatic system cancer	0.000494	0.000694	CcSEcCtD
Hydromorphone—Leukopenia—Methotrexate—lymphatic system cancer	0.000492	0.000692	CcSEcCtD
Hydromorphone—Cough—Methotrexate—lymphatic system cancer	0.00048	0.000674	CcSEcCtD
Hydromorphone—Convulsion—Methotrexate—lymphatic system cancer	0.000476	0.00067	CcSEcCtD
Hydromorphone—Chest pain—Methotrexate—lymphatic system cancer	0.000468	0.000658	CcSEcCtD
Hydromorphone—Myalgia—Methotrexate—lymphatic system cancer	0.000468	0.000658	CcSEcCtD
Hydromorphone—Arthralgia—Methotrexate—lymphatic system cancer	0.000468	0.000658	CcSEcCtD
Hydromorphone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000465	0.000654	CcSEcCtD
Hydromorphone—Discomfort—Methotrexate—lymphatic system cancer	0.000462	0.00065	CcSEcCtD
Hydromorphone—Confusional state—Methotrexate—lymphatic system cancer	0.000452	0.000636	CcSEcCtD
Hydromorphone—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000449	0.000631	CcSEcCtD
Hydromorphone—Infection—Methotrexate—lymphatic system cancer	0.000446	0.000627	CcSEcCtD
Hydromorphone—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00044	0.000619	CcSEcCtD
Hydromorphone—Skin disorder—Methotrexate—lymphatic system cancer	0.000436	0.000613	CcSEcCtD
Hydromorphone—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000434	0.00061	CcSEcCtD
Hydromorphone—Anorexia—Methotrexate—lymphatic system cancer	0.000428	0.000601	CcSEcCtD
Hydromorphone—Hypotension—Methotrexate—lymphatic system cancer	0.000419	0.000589	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000409	0.000575	CcSEcCtD
Hydromorphone—Insomnia—Methotrexate—lymphatic system cancer	0.000406	0.000571	CcSEcCtD
Hydromorphone—Paraesthesia—Methotrexate—lymphatic system cancer	0.000403	0.000566	CcSEcCtD
Hydromorphone—Dyspnoea—Methotrexate—lymphatic system cancer	0.0004	0.000562	CcSEcCtD
Hydromorphone—Somnolence—Methotrexate—lymphatic system cancer	0.000399	0.000561	CcSEcCtD
Hydromorphone—Dyspepsia—Methotrexate—lymphatic system cancer	0.000395	0.000555	CcSEcCtD
Hydromorphone—Decreased appetite—Methotrexate—lymphatic system cancer	0.00039	0.000548	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000387	0.000545	CcSEcCtD
Hydromorphone—Fatigue—Methotrexate—lymphatic system cancer	0.000387	0.000544	CcSEcCtD
Hydromorphone—Pain—Methotrexate—lymphatic system cancer	0.000384	0.000539	CcSEcCtD
Hydromorphone—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00037	0.00052	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000367	0.000516	CcSEcCtD
Hydromorphone—Urticaria—Methotrexate—lymphatic system cancer	0.000356	0.000501	CcSEcCtD
Hydromorphone—Abdominal pain—Methotrexate—lymphatic system cancer	0.000355	0.000499	CcSEcCtD
Hydromorphone—Body temperature increased—Methotrexate—lymphatic system cancer	0.000355	0.000499	CcSEcCtD
Hydromorphone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000331	0.000465	CcSEcCtD
Hydromorphone—Asthenia—Methotrexate—lymphatic system cancer	0.000322	0.000453	CcSEcCtD
Hydromorphone—Pruritus—Methotrexate—lymphatic system cancer	0.000317	0.000446	CcSEcCtD
Hydromorphone—Diarrhoea—Methotrexate—lymphatic system cancer	0.000307	0.000432	CcSEcCtD
Hydromorphone—Dizziness—Methotrexate—lymphatic system cancer	0.000297	0.000417	CcSEcCtD
Hydromorphone—Vomiting—Methotrexate—lymphatic system cancer	0.000285	0.000401	CcSEcCtD
Hydromorphone—Rash—Methotrexate—lymphatic system cancer	0.000283	0.000398	CcSEcCtD
Hydromorphone—Dermatitis—Methotrexate—lymphatic system cancer	0.000283	0.000397	CcSEcCtD
Hydromorphone—Headache—Methotrexate—lymphatic system cancer	0.000281	0.000395	CcSEcCtD
Hydromorphone—Nausea—Methotrexate—lymphatic system cancer	0.000267	0.000375	CcSEcCtD
